Seven Years of Evidence Show Jail Opioid Treatment Saves Lives and Cuts Recidivism

When Massachusetts became the first state to require certain county jails to provide every FDA-approved medication for opioid use disorder, researchers seized a rare opportunity to follow what happened next. A new commentary in Harm Reduction Journal distills seven years of findings from the Massachusetts Justice Community Opioid Innovation Network, or MassJCOIN, a federally funded research hub that partnered with seven pilot jails, the Massachusetts Department of Public Health, and community treatment providers. The verdict, drawn from a Type 1 hybrid effectiveness-implementation study, is striking: treating opioid use disorder behind bars improved treatment engagement, reduced recidivism, and saved lives.

The legal foundation came from Chapter 208 of the Acts of 2018, which established a four-year pilot program requiring five jails to deliver buprenorphine, methadone, and naltrexone, with two more jails voluntarily joining. The law stipulated that jails continue medications for individuals already receiving them before detention, initiate treatment before release among sentenced individuals where appropriate, and facilitate continuation in the community after release. Implementation unfolded within a distinctive environment that included statutory requirements, some financial support, state agency involvement, community-based treatment partners, and broader statewide support for medication access.

The strongest quantitative evidence comes from a longitudinal treatment outcome study covering all seven jails. Researchers collected data on 6,383 incarcerated people with opioid use disorder who were jailed between September 2019 and December 2020 and released before July 2021, with six months of post-release follow-up. Among them, 2,723 people, or 43 percent, received medication treatment in jail, while 3,660, or 57 percent, did not. Receipt of medication in jail was associated with an increased likelihood of initiating treatment after release and with decreased risks of opioid overdose, reincarceration, and death from any cause. The authors argue these outcomes support expanding jail-based medication programs nationwide.

How the programs were built matters as much as whether they existed. Guided by the Exploration, Preparation, Implementation, Sustainment framework, the implementation study drew on jail staff surveys with 111 respondents and in-depth qualitative interviews with 245 jail staff, 52 currently and 38 formerly incarcerated individuals, and 36 community treatment staff. One recurring lesson concerned universal access: patients and staff recommended offering medication to every person with opioid use disorder at intake, including pre-trial detainees, with assessment and new inductions within 24 hours of jail entry. Early implementation varied considerably across sites, with few jails initially conducting inductions at entry or proactively reaching out to pre-trial individuals.

Leadership proved decisive. In interviews with 11 county sheriffs, researchers found that when carceral institutional culture obstructed medication programs, sheriffs countered negative perceptions through staff education and reallocation and by building in-house programs to secure buy-in. Sheriffs also identified strong external partnerships, including peer jails, community providers, and state and national organizations, as integral to planning, launching, and sustaining programs. Staffing was another pillar: jails hired additional correctional officers, medication clinicians, substance use counselors, and reentry navigators, and implementation succeeded where staff were open to the work and experienced with substance use and mental health conditions. Younger correctional officers were more accepting of the medications, partly because of lived experience with addiction among family and friends, and jails offered extensive ongoing education and training to improve attitudes among skeptical staff.

Diversion, the concern most often cited by carceral officials for avoiding these programs, turned out to be less formidable than feared. Jail staff and formerly incarcerated patients perceived diversion, particularly of buprenorphine, as occurring less often than expected and reducible with appropriate protocols. The availability of prescribed medication itself reduced the incentive, because some demand for diverted medication came from people seeking to self-treat withdrawal. Researchers identified best practices for supervising delivery, and patients valued treatment agreements reviewed before induction that clearly communicated expectations and consequences. Recommendations emphasized therapeutic rather than punitive responses, including graduated consequences for actual and attempted diversion rather than immediate dose reductions, and healthcare that promotes patient dignity and respect.

Patient preferences shaped medication choice in ways that revealed both opportunities and inequities. Qualitative work on long-acting injectable buprenorphine found that favorable patients appreciated avoiding the taste of sublingual tablets, the indignities of daily dosing, and daily reminders of their addiction, along with fewer withdrawal symptoms, more time for work, and reduced diversion opportunities. Skeptics preferred their daily dosing routine, wanted to know what was going into their bodies, and feared needles and adverse events. Notably, participants reported that some jail clinicians used the injectable form for patients previously caught diverting sublingual buprenorphine, suggesting limited patient participation in treatment decisions in some facilities. Researchers also documented how medication provision interacted with mental health services, reducing acute intake needs by preventing withdrawal symptoms and thereby lowering suicide risk and behavioral instability, while counseling requirements, sometimes shaped by erroneous staff beliefs that counseling is always clinically necessary, shifted service demands later into incarceration.

The outer context proved as important as the jail walls. Participants acknowledged that the legislative mandate, which covered nearly half of all state jails, facilitated implementation, and lawsuits and settlements with the Department of Justice drove further change. The U.S. Attorney for Massachusetts issued a statewide compliance effort, aligned with federal civil rights protections for uninterrupted medication access under the Americans with Disabilities Act, requiring all state and county correctional facilities to maintain treatment for people already prescribed it before custody. By April 2022, all remaining correctional facilities in Massachusetts provided access to all three medication types. Community-based providers, meanwhile, described widespread staffing shortages and the challenge of collaborating with opaque, highly hierarchical jail organizations, while re-entry planning, last dose letters, bridge prescriptions, and transportation access facilitated continuity of care after release, against barriers such as insurance delays, missing identification, and poor communication between jail and community providers.

Costs emerged as a practical blueprint for other jurisdictions. Researchers identified three service delivery models: jails contracting with a vendor to administer daily methadone while clinical staff handled buprenorphine and naltrexone; facilities contracting a certified vendor to run an in-house opioid treatment program delivering all three medications; and jails obtaining their own internal certifications and licenses through a complex regulatory process. Implementation costs differed substantially across sites due to changing models, dispensary construction, and software development. Once programs reached the sustainment phase, monthly per-patient costs ranged from 93 to 242 dollars, excluding one-time fixed start-up costs. A publicly available budget impact tool lets decision-makers build facility-specific budgets and weigh trade-offs between models.

The commentary’s authors frame these findings as a playbook for jurisdictions beginning to offer medication treatment in carceral settings, while cautioning that Massachusetts’s unique legislative framework may limit transferability. Few US jails currently offer these medications even when an incarcerated person requests them, contrary to current guidance. Work in progress includes comparative effectiveness studies of the three medication types, documentation of racial and ethnic disparities in treatment receipt, and identification of implementation strategies to reach all incarcerated individuals equitably. Within a harm reduction framework, the researchers argue, jail-based medication treatment can fill gaps in public health prevention and clinical care, positioning carceral systems to work for the common good, garner public trust, and become part of the solution to the opioid overdose crisis rather than a contributor to it.

Subject of Research: Implementation, outcomes, and costs of a state-mandated jail-based medications for opioid use disorder program in Massachusetts

Article Title: Jail-based opioid treatment implementation, outcomes, and costs: lessons learned from the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)

Article References: Evans, E. A., Stopka, T. J., Pivovarova, E., Ryan, D., Murphy, S. M., Jaffe, K., Bernson, D., Bovell-Ammon, B., McCollister, K. E., Bianchet, E., Hoskinson, R., Jr, & Friedmann, P. D. (2026). Jail-based opioid treatment implementation, outcomes, and costs: lessons learned from the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). Harm Reduction Journal, 23(1), Article 167. https://doi.org/10.1186/s12954-026-01566-z

Image Credits: AI Generated

DOI: 10.1186/s12954-026-01566-z

Keywords: opioid use disorder, jail-based treatment, MOUD, buprenorphine, methadone, naltrexone, MassJCOIN, harm reduction, recidivism, overdose prevention, re-entry planning, implementation science